Search results
NCCN Guidelines® Insights - Cervical Cancer, Version 1.2024. Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix.
CERVICAL CANCER - GUIDELINES 1 Introduction Cervical cancer is uncommon in Europe but still represents a major public health problem1. The estimated number of new cervical cancer cases in Europe in 2012 was 58 348 with 24 397 deaths2. Five-year relative survival for European women diagnosed with cervical cancer in 2000-2007 was 62%, ranging ...
jointly developed clinically relevant and evidence-based guidelines covering comprehensively cervical cancer staging, management and follow-up for patients with cervical. Management includes fertility sparing treatment, stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy, locally advanced
cervical cancer, but traditionally the condition mainly affected sexually active women aged between 30 and 45 years of age, however, recent data from Cancer Research UK shows the peak age of incidence has reduced to 25-29 years of age. Cervical cancer is very rare in women under 25 years old (4) and
Following the launch of the Global Strategy, a large panel of experts met to define the key areas of screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition .
The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic feature ….
These NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer, Version 1.2024 – September 20, 2023. View the NCCN Guidelines for Patients free online.
